Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Notes Payables: 2020-2022

Historic Notes Payables for Seres Therapeutics (MCRB) over the last 2 years, with Dec 2022 value amounting to $456,000.

  • Seres Therapeutics' Notes Payables was N/A to $456,000 in Q4 2022 from the same period last year, while for Dec 2022 it was $456,000, marking a year-over-year change of. This contributed to the annual value of $456,000 for FY2022, which is N/A change from last year.
  • Latest data reveals that Seres Therapeutics reported Notes Payables of $456,000 as of FY2022, which was up 0.44% from $454,000 recorded in FY2020.
  • In the past 5 years, Seres Therapeutics' Notes Payables registered a high of $456,000 during FY2022, and its lowest value of $454,000 during FY2020.
  • Its 2-year average for Notes Payables is $455,000, with a median of $455,000 in 2020.